13F Holdings
中文EN

AZN ASTRAZENECA PLC IFRS

Pharmaceutical Preparations · NYSE · SEC CIK 901832 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.6%
TTM net income YoY45.3%
TTM EPS YoY45.3%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR46.0%

Margins

Gross margin81.9%
Operating margin23.4%
Net margin17.4%
FCF margin20.0%
EBITDA margin—

Returns

ROE22.9%
ROA9.4%
ROIC (approx.)16.8%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets57.3%
Debt / equity0.57x
Current ratio0.94x
Interest coverage8.11x

Cash quality & payout

Operating cash flow / net income1.43x
Accruals ratio-4.0%
Payout ratio48.6%
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$58.74B$54.07B$45.81B$44.35B$37.42B
Cost of revenue$10.63B$10.21B$8.27B$12.39B$12.44B
Gross profit$48.11B$43.87B$37.54B$31.96B$24.98B
R&D expense$14.23B$13.58B$10.94B$9.76B$9.74B
SG&A expense$19.93B$19.98B$19.22B$18.42B$15.23B
Operating income$13.74B$10.00B$8.19B$3.76B$1.06B
Interest expense$1.69B$1.74B$1.63B$1.35B$1.30B
Pretax income$12.40B$8.69B$6.90B$2.50B-$265.00M
Income tax$2.17B$1.65B$938.00M-$792.00M-$380.00M
Net income$10.22B$7.04B$5.96B$3.29B$112.00M
EPS (basic)6.604.543.842.120.08
EPS (diluted)6.544.503.812.110.08
Dividends declared per share3.132.972.902.902.80
Weighted avg. shares (diluted)1.56B1.56B1.56B1.56B1.43B
Balance sheet
Cash & equivalents$5.71B$5.49B$5.84B$6.17B$6.33B
Short-term investments$30.00M$166.00M$122.00M$239.00M$69.00M
Receivables$15.18B$12.97B$12.13B$10.52B$9.64B
Inventory$6.56B$5.29B$5.42B$4.70B$8.98B
Current assets$28.72B$25.83B$25.05B$22.59B$26.24B
PP&E, netmay include right-of-use assets (IFRS)$12.96B$10.25B$9.40B$8.51B$9.18B
Goodwill$21.24B$21.02B$20.05B$19.82B$20.00B
Intangibles$37.85B$37.18B$38.09B$39.31B$42.49B
Total assets$114.07B$104.03B$101.12B$96.48B$105.36B
Current liabilities$30.62B$27.87B$30.54B$26.29B$22.59B
Short-term debt$3.10B$2.34B$5.13B$5.31B$1.66B
Long-term debt$24.71B$26.51B$22.36B$22.96B$28.13B
Total debt$27.82B$28.84B$27.49B$28.28B$29.79B
Total liabilities$65.36B$63.16B$61.95B$59.42B$66.08B
Shareholders' equity$48.67B$40.79B$39.14B$37.04B$39.27B
Net debt$22.11B$23.36B$21.65B$22.11B$23.46B
Cash flow statement
Operating cash flow$14.57B$11.86B$10.35B$9.81B$5.96B
Capital expenditure$2.81B$1.92B$1.36B$1.09B$1.09B
Free cash flow$11.77B$9.94B$8.98B$8.72B$4.87B
Investing cash flow-$6.81B-$7.98B-$4.06B-$2.96B-$11.06B
Financing cash flow-$7.54B-$4.00B-$6.57B-$6.82B$3.65B
Stock-based compensation$719.00M$660.00M$579.00M$619.00M$615.00M
Dividends paid$4.97B$4.63B$4.48B$4.36B$3.86B
Share buybacks$521.00M$81.00M——$149.00M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.